File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials

TitleClinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
Authors
KeywordsBiomarker endpoint analysis
Breast cancer
Neoadjuvant endocrine therapy
Issue Date2005
Citation
Journal of Steroid Biochemistry and Molecular Biology, 2005, v. 95, n. 1-5, p. 91-95 How to Cite?
AbstractNeoadjuvant endocrine therapy trials for breast cancer are now a widely accepted investigational approach for oncology cooperative group and pharmaceutical company research programs. However, there remains considerable uncertainty regarding the most suitable endpoints for these studies, in part, because short-term clinical, radiological or biomarker responses have not been fully validated as surrogate endpoints that closely relate to long-term breast cancer outcome. This shortcoming must be addressed before neoadjuvant endocrine treatment can be used as a triage strategy designed to identify patients with endocrine therapy "curable" disease. In this summary, information from published studies is used as a basis to critique clinical trial designs and to suggest experimental endpoints for future validation studies. Three aspects of neoadjuvant endocrine therapy designs are considered: the determination of response; the assessment of surgical outcomes; and biomarker endpoint analysis. Data from the letrozole 024 (LET 024) trial that compared letrozole and tamoxifen is used to illustrate a combined endpoint analysis that integrates both clinical and biomarker information. In addition, the concept of a "cell cycle response" is explored as a simple post-treatment endpoint based on Ki67 analysis that might have properties similar to the pathological complete response endpoint used in neoadjuvant chemotherapy trials. © 2005 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/315961
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.925
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTao, Yu-
dc.contributor.authorKlause, Andreas-
dc.contributor.authorVickers, Andrew-
dc.contributor.authorBae, Kyongtae-
dc.contributor.authorEllis, Matthew-
dc.date.accessioned2022-08-24T15:48:44Z-
dc.date.available2022-08-24T15:48:44Z-
dc.date.issued2005-
dc.identifier.citationJournal of Steroid Biochemistry and Molecular Biology, 2005, v. 95, n. 1-5, p. 91-95-
dc.identifier.issn0960-0760-
dc.identifier.urihttp://hdl.handle.net/10722/315961-
dc.description.abstractNeoadjuvant endocrine therapy trials for breast cancer are now a widely accepted investigational approach for oncology cooperative group and pharmaceutical company research programs. However, there remains considerable uncertainty regarding the most suitable endpoints for these studies, in part, because short-term clinical, radiological or biomarker responses have not been fully validated as surrogate endpoints that closely relate to long-term breast cancer outcome. This shortcoming must be addressed before neoadjuvant endocrine treatment can be used as a triage strategy designed to identify patients with endocrine therapy "curable" disease. In this summary, information from published studies is used as a basis to critique clinical trial designs and to suggest experimental endpoints for future validation studies. Three aspects of neoadjuvant endocrine therapy designs are considered: the determination of response; the assessment of surgical outcomes; and biomarker endpoint analysis. Data from the letrozole 024 (LET 024) trial that compared letrozole and tamoxifen is used to illustrate a combined endpoint analysis that integrates both clinical and biomarker information. In addition, the concept of a "cell cycle response" is explored as a simple post-treatment endpoint based on Ki67 analysis that might have properties similar to the pathological complete response endpoint used in neoadjuvant chemotherapy trials. © 2005 Elsevier Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofJournal of Steroid Biochemistry and Molecular Biology-
dc.subjectBiomarker endpoint analysis-
dc.subjectBreast cancer-
dc.subjectNeoadjuvant endocrine therapy-
dc.titleClinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials-
dc.typeConference_Paper-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jsbmb.2005.04.017-
dc.identifier.pmid15994076-
dc.identifier.scopuseid_2-s2.0-23744448408-
dc.identifier.volume95-
dc.identifier.issue1-5-
dc.identifier.spage91-
dc.identifier.epage95-
dc.identifier.isiWOS:000231480700014-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats